10x Genomics (NASDAQ:TXG) made its public debut Thursday morning, opening at $54 after being priced at $39 per share.
The firm plans to trade on the Nasdaq under ticker symbol "TXG.”
See Aslo: 10X Genomics IPO: What You Need To Know
10x Genomics markets the Chromium single-cell analysis system and assay kits, announced its plans for an IPO last month. Initially, its filing said it was looking to raise up to $100 million.
JPMorgan, Goldman Sachs and Bank of America Merrill Lynch are acting as lead joint book-running managers for the offering. Cowen is acting as lead manager for the offering.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
